Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro

Dig Dis Sci. 2012 Jun;57(6):1604-8. doi: 10.1007/s10620-012-2159-7. Epub 2012 Apr 26.

Abstract

Background: Infliximab-induced hepatotoxicity is reported in several case studies involving patients with inflammatory bowel disease (IBD) and a direct hepatotoxic effect has been proposed.

Objective: The aim of this study was to determine the direct in vitro toxicity of infliximab. As a proof of principle the in vitro toxicity of thiopurines and methotrexate was also determined.

Methods: Cell survival curves and the half maximal inhibitory concentrations (IC(50)) were obtained after 24, 48 and 72 h of incubation in HepG2 cells with the IBD drugs azathioprine, 6-mercaptopurine, 6-thioguanine, methotrexate or infliximab by using the WST-1 cytotoxicity assay.

Results: No in vitro hepatotoxicity in HepG2 cells was seen with infliximab, while concentration-dependent cytotoxicity was observed when HepG2 cells were incubated with increasing concentrations of azathioprine, 6-mercaptopurine and 6-thioguanine.

Conclusion: Infliximab alone or given in combination with azathioprine showed no direct hepatotoxic effect in vitro, indicating that the postulated direct hepatotoxicity of infliximab is unlikely.

Publication types

  • Comparative Study

MeSH terms

  • Analysis of Variance
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / toxicity*
  • Azathioprine / pharmacology
  • Azathioprine / toxicity
  • Cell Survival / drug effects*
  • Dose-Response Relationship, Drug
  • Hep G2 Cells / drug effects*
  • Hepatoblastoma / chemically induced
  • Humans
  • In Vitro Techniques
  • Inflammatory Bowel Diseases / diagnosis
  • Inflammatory Bowel Diseases / drug therapy
  • Infliximab
  • Liver Neoplasms / chemically induced
  • Mercaptopurine / pharmacology
  • Mercaptopurine / toxicity
  • Methotrexate / pharmacology
  • Methotrexate / toxicity
  • Sensitivity and Specificity
  • Thioguanine / pharmacology
  • Thioguanine / toxicity

Substances

  • Antibodies, Monoclonal
  • Infliximab
  • Mercaptopurine
  • Thioguanine
  • Azathioprine
  • Methotrexate